Rice Hall James & Associates LLC Has $6.60 Million Position in Urogen Pharma $URGN

Rice Hall James & Associates LLC grew its holdings in shares of Urogen Pharma (NASDAQ:URGN) by 8.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 281,876 shares of the company’s stock after acquiring an additional 22,733 shares during the period. Rice Hall James & Associates LLC’s holdings in Urogen Pharma were worth $6,602,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Urogen Pharma by 27.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,275 shares of the company’s stock worth $53,000 after acquiring an additional 486 shares during the period. Russell Investments Group Ltd. increased its holdings in Urogen Pharma by 1,594.4% in the third quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock worth $66,000 after purchasing an additional 3,125 shares in the last quarter. Osaic Holdings Inc. increased its holdings in Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock worth $50,000 after purchasing an additional 3,070 shares in the last quarter. Tower Research Capital LLC TRC increased its holdings in Urogen Pharma by 422.0% in the second quarter. Tower Research Capital LLC TRC now owns 6,891 shares of the company’s stock worth $94,000 after purchasing an additional 5,571 shares in the last quarter. Finally, ProShare Advisors LLC bought a new stake in Urogen Pharma in the fourth quarter worth approximately $206,000. 91.29% of the stock is currently owned by institutional investors and hedge funds.

Urogen Pharma Price Performance

Shares of URGN opened at $30.86 on Tuesday. The stock has a 50-day moving average of $25.96 and a 200-day moving average of $22.86. The company has a market cap of $1.50 billion, a PE ratio of -11.22 and a beta of 1.59. Urogen Pharma has a one year low of $12.61 and a one year high of $32.37.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Thursday, May 7th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.01. The firm had revenue of $50.96 million during the quarter, compared to analyst estimates of $44.83 million. Analysts expect that Urogen Pharma will post -0.98 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $45.00 target price on shares of Urogen Pharma in a report on Wednesday, June 3rd. D. Boral Capital reiterated a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a report on Tuesday, March 31st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. Oppenheimer reiterated an “outperform” rating on shares of Urogen Pharma in a report on Tuesday, June 2nd. Finally, Jefferies Financial Group upgraded Urogen Pharma to a “strong-buy” rating in a report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Insider Activity at Urogen Pharma

In other news, insider Mark Schoenberg sold 5,222 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $27.30, for a total value of $142,560.60. Following the completion of the sale, the insider directly owned 139,763 shares in the company, valued at $3,815,529.90. This trade represents a 3.60% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 4.80% of the stock is currently owned by corporate insiders.

Urogen Pharma Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.